A resolution to authorize the production of records by the Committee on Foreign Relations.
- Last Action
- 5/14/2025
Actions
- 2025-01-23Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)
- 2025-01-23Introduced in Senate
CRS Summary
As of 2025-01-23 (00)
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Cosponsors (9)
- Chuck Grassley (R-IA)
- Angus King (I-ME)
- Joni Ernst (R-IA)
- Tina Smith (D-MN)
- Peter Welch (D-VT)
- Richard Blumenthal (D-CT)
- Tammy Baldwin (D-WI)
- Tommy Tuberville (R-AL)
- Cindy Hyde-Smith (R-MS)
Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Department of Health and Human Services
- Health care costs and insurance
- Marketing and advertising
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.